特利加压素联合雷贝拉唑对肝硬化门静脉高压食管胃静脉曲张出血患者凝血功能及血清炎症因子水平的影响  

Effects of Terlipressin Combined with Rabeprazole on Coagulation Function and Serum Inflammatory Factors in Patients with Liver Cirrhosis Complicated with Esophagogastric Variceal Bleeding

作　　者：仝国栋 杨梅 TONG Guodong;YANG Mei(The Fifth People's Hospital of Anyang,Anyang Henan 455000,China)

机构地区：[1]安阳市第五人民医院,河南安阳455000

出　　处：《药品评价》2024年第8期1023-1026,共4页Drug Evaluation

摘　　要：目的分析特利加压素联合雷贝拉唑对肝硬化并发门静脉高压食管胃静脉曲张出血(EGVB)患者凝血功能及血清炎症因子水平的影响。方法选取2021年5月至2023年7月于安阳市第五人民医院诊疗的肝硬化并发EGVB患者80例,根据治疗方案不同分为对照组(40例)、观察组(40例)。其中予以雷贝拉唑的40例为对照组,予以特利加压素+雷贝拉唑的40例为观察组。比较两组临床疗效、治疗前后凝血纤溶功能、门静脉系统血流动力学、血清炎症因子水平及不良反应发生率。结果观察组临床总有效率95.00%高于对照组77.50%(P<0.05)。治疗后,观察组凝血纤溶功能改善程度优于对照组(P<0.05);观察组门静脉系统血流动力学低于对照组(P<0.05);观察组血清炎症因子水平降低幅度大于对照组(P<0.05)。观察组不良反应发生率17.50%与对照组7.50%相比,差异无统计学意义(P>0.05)。结论特利加压素联合雷贝拉唑治疗肝硬化并发EGVB疗效明显,可调节凝血纤溶功能,改善门静脉系统血流动力学,减轻炎症反应,并具有一定安全性。Objective To analyze the effects of terlipressin combined with rabeprazole on the coagulation function and serum inflammatory factor levels in patients with liver cirrhosis(LC)complicated with esophagogastric variceal bleeding(EGVB).Methods A total of 80 patients with LC complicated with EGVB who were treated in The Fifth People's Hospital of Anyang from May 2021 to July 2023 were selected and divided into control group(40 cases)and observation group(40 cases)according to different treatment schemes.Among them,40 cases were given rabeprazole as the control group,and 40 cases were given terlipressin combined with rabeprazole as the observation group.The clinical efficacy of the two groups were compared,as well as the levels of coagulation and fibrinolysis function,portal hemodynamics,serum inflammatory factors before and after treatment,and the incidence of adverse reactions was also compared between the two groups.Results The clinical total effective rate of the observation group was 95.00%higher than 77.50%of the control group(P<0.05).After treatment,the improvement of coagulation and fibrinolysis function in the observation group was better than that in the control group(P<0.05);the hemodynamics of portal vein system in the observation group was lower than that in the control group(P<0.05);the reduction of serum inflammatory factors in the observation group was greater than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 17.50%compared with 7.50%in the control group,with no significant difference(P>0.05).Conclusion Terlipressin combined with rabeprazole has obvious curative effect in the treatment of LC complicated with EGVB,which can regulate the coagulation and fibrinolysis function,improve the hemodynamics of portal vein system,reduce the inflammatory reaction,and has certain safety.

关 键 词：特利加压素 雷贝拉唑 肝硬化 门静脉高压食管胃静脉曲张出血 凝血功能 

分 类 号：R575.2[医药卫生—消化系统]